The Next Step of Their Control Is Here …

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

Saqib Islam Biography and Net Worth

CEO of SpringWorks Therapeutics

Saqib Islam was appointed Chief Executive Officer of SpringWorks Therapeutics in 2018. He was a founding member of the company’s executive team since its launch in 2017 and previously served as Chief Financial Officer and Chief Business Officer of the company. Prior to joining SpringWorks, Saqib was Chief Business Officer at Moderna Therapeutics, where he oversaw critical aspects of the company’s growth, including global strategic planning, corporate development and business development. Prior to Moderna, Saqib served as Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, executing the company’s corporate growth strategies and contributing to its assessment and management of global operations. Saqib has over 25 years of international business management experience and an extensive background in the healthcare banking sector, having held managing director positions in the investment banking divisions of Morgan Stanley and Credit Suisse Securities. He currently serves on the Board of Directors of ARYA Sciences Acquisition Corp III, Passage Bio (where he also serves as a member of its Audit Committee), and Silverback Therapeutics (where he also serves as a member of its Compensation Committee).

Saqib received his bachelor’s degree from McGill University, graduating as a Faculty and University Scholar, and a J.D. from Columbia Law School, where he was a Harlan Fiske Stone Scholar.

What is Saqib Islam's net worth?: The estimated net worth of Saqib Islam is at least $41.35 million as of April 19th, 2021. Mr. Islam owns 908,127 shares of SpringWorks Therapeutics stock worth more than $41,347,022 as of April 26th. This net worth estimate does not reflect any other assets that Mr. Islam may own. Additionally, Mr. Islam receives a salary of $1,260,000.00 as CEO at SpringWorks Therapeutics. Learn More about Saqib Islam's net worth.
How old is Saqib Islam?: Mr. Islam is currently 54 years old. There are 7 older executives and no younger executives at SpringWorks Therapeutics. Learn More on Saqib Islam's age.
What is Saqib Islam's salary?: As the CEO of SpringWorks Therapeutics, Inc., Mr. Islam earns $1,260,000.00 per year. Learn More on Saqib Islam's salary.
How do I contact Saqib Islam?: The corporate mailing address for Mr. Islam and other SpringWorks Therapeutics executives is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. SpringWorks Therapeutics can also be reached via phone at 203-883-9490 and via email at [email protected]. Learn More on Saqib Islam's contact information.
Has Saqib Islam been buying or selling shares of SpringWorks Therapeutics?: Saqib Islam has not been actively trading shares of SpringWorks Therapeutics during the last quarter. Most recently, Saqib Islam sold 10,083 shares of the business's stock in a transaction on Wednesday, October 20th. The shares were sold at an average price of $58.67, for a transaction totalling $591,569.61. Learn More on Saqib Islam's trading history.
Who are SpringWorks Therapeutics' active insiders?: SpringWorks Therapeutics' insider roster includes Badreddin Edris (COO), Julie Hambleton (Director), Saqib Islam (CEO), Daniel Pichl (Chief People Officer), L. Smith (Insider), and Stephen Squinto (Director). Learn More on SpringWorks Therapeutics' active insiders.
Are insiders buying or selling shares of SpringWorks Therapeutics?: In the last year, insiders at the sold shares 3 times. They sold a total of 19,818 shares worth more than $886,979.58. The most recent insider tranaction occured on February, 16th when insider Daniel Pichl sold 15,000 shares worth more than $751,500.00. Insiders at SpringWorks Therapeutics own 7.6% of the company. Learn More about insider trades at SpringWorks Therapeutics.
Information on this page was last updated on 2/16/2024.

Saqib Islam Insider Trading History at SpringWorks Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/20/2021	Sell	10,083	$58.67	$591,569.61
10/18/2021	Sell	38,340	$58.59	$2,246,340.60
7/19/2021	Sell	43,928	$76.09	$3,342,481.52
4/19/2021	Sell	38,425	$69.04	$2,652,862.00	908,127
1/19/2021	Sell	60,301	$78.54	$4,736,040.54	1,225,196

Saqib Islam Buying and Selling Activity at SpringWorks Therapeutics

SpringWorks Therapeutics Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $45.53

$43.44

$46.04

50 Day Range

MA: $47.75

$40.10

$52.50

2 Week Range

Now: $45.53

$18.00

$53.92

Volume

898,993 shs

Average Volume

1,094,884 shs

Market Capitalization

$3.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

The Next Step of Their Control Is Here …

From Weiss Ratings | Ad

4 simple steps to protect your privacy and money before it’s too late.

Saqib Islam Biography and Net Worth

What is Saqib Islam's net worth?

How old is Saqib Islam?

What is Saqib Islam's salary?

How do I contact Saqib Islam?

Has Saqib Islam been buying or selling shares of SpringWorks Therapeutics?

Who are SpringWorks Therapeutics' active insiders?

Are insiders buying or selling shares of SpringWorks Therapeutics?